Orion Infusions (DHA:ORIONINFU) EPS (Basic): BDT1.74 (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:ORIONINFU Orion Infusions Ltd DHA:ORIONINFU
81 GF Score
Price BDT291.20
GF Value BDT316.17
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Orion Infusions EPS (Basic)?

Orion Infusions DHA:ORIONINFU +0.10% 81 EPS (Basic) is BDT1.74 as of Mar. 2026. GuruFocus rates DHA:ORIONINFU with a GF Score™ of 81/100 and a GF Value™ of BDT316.17 (Fairly Valued). The stock has 3 warning signs investors should review.

Orion Infusions's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was BDT0.27. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was BDT1.74.

Orion Infusions's EPS (Diluted) for the three months ended in Mar. 2026 was BDT0.27. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was BDT1.74.

Orion Infusions's EPS without NRI for the three months ended in Mar. 2026 was BDT0.27. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 1.72.

During the past 12 months, Orion Infusions's average EPS without NRIGrowth Rate was -15.40% per year. During the past 3 years, the average EPS without NRI Growth Rate was -6.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was 5.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was -1.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Orion Infusions's highest 3-Year average EPS without NRI Growth Rate was 60.50% per year. The lowest was -27.90% per year. And the median was 1.35% per year.

Orion Infusions  (DHA:ORIONINFU) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Orion Infusions EPS (Basic) Related Terms

Orion Infusions EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Orion Infusions's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orion Infusions EPS (Basic) Chart

Orion Infusions Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.37 2.10 2.06 2.08 1.72

Orion Infusions Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.37 0.32 0.57 0.58 0.27
DHA:ORIONINFU
81GF Score
Orion Infusions Ltd DHA:ORIONINFU
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orion Infusions EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Orion Infusions's Basic EPS for the fiscal year that ended in Jun. 2025 is calculated as

Basic EPS (A: Jun. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(35.024-0)/20.360
=1.72

Orion Infusions's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(5.533-0)/20.493
=0.27

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT1.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of BDT1.74 mean?
Orion Infusions (DHA:ORIONINFU) has a EPS (Basic) of BDT1.74 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Orion Infusions and its competitors.
Is Orion Infusions' EPS (Basic) too high?
Orion Infusions' current EPS (Basic) is BDT1.74. Overall, Orion Infusions has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Orion Infusions' EPS (Basic) compare to ZTS and UTHR?
Orion Infusions' EPS (Basic) of BDT1.74 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Orion Infusions and its competitors. Orion Infusions's current EPS (Basic) is BDT1.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Infusions stock overvalued right now?
Based on GuruFocus' analysis, Orion Infusions (DHA:ORIONINFU) is currently considered Fairly Valued. The stock's GF Value™ is BDT316.17, compared to a current price of BDT291.20 — trading 7.9% below its estimated fair value. The current EPS (Basic) is BDT1.74. Orion Infusions' overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Orion Infusions (DHA:ORIONINFU), the current EPS (Basic) is BDT1.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orion Infusions (DHA:ORIONINFU) Overvalued in 2026?

Based on GuruFocus' analysis, Orion Infusions stock appears to be undervalued. The current stock price of BDT291.20 is trading 7.9% below its estimated GF Value™ of BDT316.17. GuruFocus considers Orion Infusions to be Fairly Valued.

Key valuation signals for DHA:ORIONINFU:

  • EPS (Basic): BDT1.74
  • GF Value™: BDT316.17 vs. price of BDT291.20 (7.9% below fair value)
  • GF Score™: 81/100 with 3 warning signs

No single metric tells the full story. See the DHA:ORIONINFU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orion Infusions Business Description

Address 153-154 Tejgaon Industrial Area, Orion House, Dhaka, BGD, 1208
Orion Infusions Ltd is a pharmaceutical company engaged in the production of various types of intravenous fluids, rehydration solutions, electrolyte solutions, and solutions for acidosis, as well as Ranitidine I.V. infusion and anti-microbial products such as Ciprofloxacin I.V. and Metronidazole I.V. The Company's products include Dextrolac, Dextropac, Dextrosal, Dianak, Electro Dex, Fructose, Hartman, Intralipid, Manisol, Maprocin, Nidazyl, Orlev, Ortac, Plasmasol, Proliv, and Salpac. In addition, the Group operates across several sectors, including pharma and healthcare, power and energy, infrastructure development, real estate, cosmetics and toiletries, consumer products, textiles and garments, and home appliances. Geographically, the Company operates in Bangladesh.
81GF Score

Get the complete analysis for DHA:ORIONINFU

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT291.20
Price
BDT316.17
GF Value